David Gearing
Dr. Gearing is co-founder and Chief Scientific Officer of Nexvet BioPharma, a NASDAQ-listed company committed to developing antibody therapies for companion animals. Dave has more than 20 years experience in the biopharmaceutical sector, including: as Chief Research Officer and Director of Research at CSL Ltd, a specialty biopharmaceutical company based in Melbourne, Australia; as Vice President and co-founder of Millennium Biotherapeutics, Inc., a US biopharmaceutical company; as Director of Molecular Biology at SyStemix, a US stem cell and gene therapy company; and as a Staff Scientist at Immunex Corporation, a US biopharmaceutical company.
Dave has a B.Sc. (Hons.) degree in Biochemistry from Leeds University and a Ph.D. in Biochemistry from Monash University, and also trained at the Cancer Research Unit of the Walter and Eliza Hall Institute in Melbourne, Australia.
Dave's family includes a dog named Chloe.
Abstracts this author is presenting:
